key: cord-1047290-o3u8m1k7
authors: van Veldhuisen, Sophie L.; van Woerden, Gijs; Hemels, Martin EW.; America, Yves GCJ.; de Boer, Rudolf A.; Rienstra, Michiel; van Veldhuisen, Dirk J.; Hazebroek, Eric J.
title: Preoperative Cardiac Screening using NT-proBNP in Obese Patients Aged ≥50 years Undergoing Bariatric Surgery: a Study of 310 Consecutive Patients.
date: 2020-09-02
journal: Surg Obes Relat Dis
DOI: 10.1016/j.soard.2020.08.036
sha: fe6b5a9f40b8dc382b48c0b146509027ae29ec8f
doc_id: 1047290
cord_uid: o3u8m1k7

INTRODUCTION: Obesity is associated with cardiovascular (CV) risk factors and diseases. Because bariatric surgery is increasingly performed in relatively elderly patients, a risk for per- and postoperative CV complications exists. OBJECTIVES: We aimed to assess the value of plasma N-terminal-pro hormone BNP (NT-proBNP) as a CV screening tool. SETTING: High-volume bariatric center METHODS: Between June 2019 and January 2020, all consecutive bariatric patients aged ≥50 years underwent pre-operative NT-proBNP assessment in this cohort study, to screen for CV disease. Patients with elevated NT-proBNP (≥125 pg/ml) were referred for further cardiac evaluation, including electrocardiography and echocardiography. RESULTS: We included 310 consecutive patients (median age 56 years, 79% female, body mass index 43±6.5 kg/m(2)). A history of CV disease was present in 21% of patients, mainly atrial fibrillation (7%) and coronary artery disease (10%). 72 patients (23%) had elevated NT-proBNP levels, and 67 of them underwent further cardiac work-up. Of these 67 patients, electrocardiography showed atrial fibrillation in 7 patients (10%). On echocardiography, three patients had left ventricular ejection fraction (LVEF) <40%, nine patients had LVEF 40-49%, and 13 patients had LVEF ≥50% with structural and/or functional remodeling. In two patients, elevated NT-proBNP prompted work-up leading to a diagnosis of coronary artery disease, and consequent percutaneous coronary intervention in one patient. CONCLUSION: Elevated NT-proBNP levels are present in 23% of patients ≥50 years undergoing bariatric surgery. In 37% of them, there was echocardiographic evidence for structural and/or functional remodeling. Further studies are needed to assess if these preliminary results warrant routine application of NT-proBNP to identify patients at risk for CV complications after bariatric surgery.

Obesity is associated with cardiovascular (CV) risk factors and diseases. Because bariatric surgery is increasingly performed in relatively elderly patients, a risk for per-and postoperative CV complications exists. 5

We aimed to assess the value of plasma N-terminal-pro hormone BNP (NT-proBNP) as a CV screening tool.

High-volume bariatric center 10 Methods Between June 2019 and January 2020, all consecutive bariatric patients aged ≥50 years underwent pre-operative NT-proBNP assessment in this cohort study, to screen for CV disease. Patients with elevated NT-proBNP (≥125 pg/ml) were referred for further cardiac evaluation, including electrocardiography and echocardiography. 15

We included 310 consecutive patients (median age 56 years, 79% female, body mass index 43±6.5 kg/m 2 ). A history of CV disease was present in 21% of patients, mainly atrial fibrillation (7%) and coronary artery disease (10%). 72 patients (23%) had elevated NT-proBNP levels, and 67 of them underwent further cardiac work-up. Of these 67 patients, 20 electrocardiography showed atrial fibrillation in 7 patients (10%). On echocardiography, three patients had left ventricular ejection fraction (LVEF) <40%, nine patients had LVEF 40-49%, and 13 patients had LVEF ≥50% with structural and/or functional remodeling. In two J o u r n a l P r e -p r o o f Introduction Obesity is associated with many cardiovascular (CV) risk factors such as hypertension, type 2 diabetes (T2D), dyslipidemia, and systemic inflammation [1] [2] [3] [4] . The long-term consequences of 40 these risk factors are increasingly recognized, and CV diseases such as heart failure, atrial fibrillation, coronary artery disease, but also valvular heart disease and stroke are common, particularly in the elderly. Obesity has become one of the largest healthcare problems worldwide. The prevalence of obesity (i.e. body mass index [BMI] ≥ 30 kg/m 2 ) is currently around 40%, and is still increasing [5] . As a result, obesity is increasingly recognized as a 45 serious, and potentially treatable risk factor for CV disease [1, 2] .

Treatment of obesity is difficult, and currently, bariatric surgery is the only treatment option that renders significant and durable weight loss in obese patients with relatively low peri-and post-operative complications rates [6] [7] [8] . Anastomotic leakage and bleeding are the most common reported complications early after surgery, but vascular or cardiopulmonary 50 problems can also occur [9] . The latter were reported to be present in up to 1.3% of all bariatric patients [9] , although a larger study showed that during 90-day follow-up the percentage of CV deaths was much higher compared to those caused by leakage or bowel obstruction: 10/36 deaths were "heart related" (28%), and strongly related to CV risk factors and increasing age [8] . Although the majority of patients undergoing bariatric surgery are 55 relatively young, a significant proportion of patients is older than 50 years of age, and these patients have a risk for CV diseases [10] . Given the significant number of patients with CV disease who will undergo bariatric surgery, screening for subclinical or unrecognized CV disease in patients ≥50 years may be beneficial.

J o u r n a l P r e -p r o o f patients who undergo bariatric surgery, current bariatric guidelines do not provide details regarding preoperative cardiac work-up [6, 11, 12] .

In the present study, we therefore aimed to determine the prevalence and incidence of CV diseases in patients ≥50 years who were undergoing bariatric surgery. Because cardiac examinations are not routinely performed in patients referred for bariatric surgery, 65 we investigated whether a simple marker could provide useful information. Therefore, we measured N-terminal pro Brain Natriuretic Peptide (NT-proBNP) levels in consecutive patients ≥50 years old who were scheduled to undergo bariatric surgery. This biomarker is one the most sensitive markers to detect early CV disease [13] , and has proven to be of important diagnostic value in patient groups undergoing non-cardiac (vascular) surgery [14, 70 15] .

All patients in the present study were referred to the Department of Bariatric Surgery, Rijnstate Hospital; Arnhem; the Netherlands, between June 2019 and January 2020, which is 75 a high-volume bariatric center performing around 1300 bariatric procedures per year. For this prospective cohort study, only patients who were ≥50 years old, and who fulfilled the IFSO criteria (BMI ≥ 35 kg/m 2 with an obesity related comorbidity or BMI ≥40 kg/m 2 ), were considered eligible.

The cardiac screening protocol was approved by the Local Ethics Committee, and all 80 patients gave informed consent. The present study was in concordance with the principles outlined in the Declaration of Helsinki. In patients who were deemed eligible, plasma NT-proBNP samples were collected and NT-proBNP concentrations in blood samples were J o u r n a l P r e -p r o o f measured by the Atellica® IM PBNP Essay, using the Atellica IM Analyzer (Siemens Healthineers, Erlangen, Germany). If the NT-proBNP value was 125 pg/ml or higher, patients 85 were referred to the Department of Cardiology, Rijnstate Hospital for further cardiac workup. This cut-off point is advocated by the European Society of Cardiology (ESC) for excluding heart failure. Although several confounders for NT-proBNP levels are known, including age, fat mass, and sex, this cut-off point has been shown to provide a reasonable performance [16, 17] . 90

If patients were referred to the cardiologist, a 12-lead standard electrocardiogram (ECG) was performed, as well as an echocardiogram. Transthoracic 2-and 3-Dimensional echocardiography was performed using Epiq Philips (EPIQ 7C Hardware en software version 5.02). HeartModel software was used to measure left ventricular (LV) and left atrial global volume at end-diastole and at end-systole, and to calculate the left ventricular ejection 95 fraction (LVEF). All measurements were assessed according to the current recommendations for cardiac chamber quantification and assessment of diastolic function [18] , and included LV systolic function (in particular LVEF), tricuspid annular plane systolic excursion for right ventricular function, and left ventricular diastolic function (E, A, E/A ratio, e', and E/e' ratio), valvular stenosis and/or regurgitation, and the peak pressure gradient across the tricuspid 100 valve. Left atrial enlargement was defined as ≥34 ml/m 2 , LV hypertrophy as LV mass index >95g/m 2 for women and >115g/m 2 for men, and diastolic dysfunction as mean septal and lateral 'e <9cm/s and/or E/e' >13, all according to the current ESC criteria [19] .

Heart failure was documented if patients had LVEF <40% ("heart failure with reduced LVEF, or systolic heart failure"), or LVEF 40-49% ("heart failure with mid-range EF"), or if they 105 fulfilled the criteria of heart failure with preserved LVEF, i.e. ≥50%, and additional echocardiographic evidence for relevant structural heart disease, including LV hypertrophy J o u r n a l P r e -p r o o f and/or left atrial enlargement and/or diastolic dysfunction, as described earlier in this section. [19] .

Besides electrocardiography and echocardiography, additional diagnostic tests or 110 interventions were performed when deemed necessary. Adverse events during the first 30 days after surgery were documented. We had particular interest in cardiovascular and pulmonary adverse events, including severe arrhythmias, acute heart failure, acute coronary syndrome, stroke or transient ischemic attack, pneumonia, deep vein thrombosis or pulmonary embolism, acute renal failure and reintubation. Severity of adverse events were 115 scored according to the Clavien Dindo Classification, minor and major complications were respectively defined as class 1-2 and class ≥3A [20] .

Normally and non-normally distributed data were described using means with standard deviations (SD) and medians with interquartile ranges (IQR). Continuous data were analyzed using independent t-tests, Mann Whitney U test or a Fishers' exact test, depending on the 120 distribution. A p value of < 0.05 was considered as statistically significant. Statistical analyses were performed by using IBM SPSS Statistics, version 25.0 for Windows (SPSS. Chicago, IL).

Between June 2019 and January 2020, NT-proBNP levels were assessed in 310 consecutive patients referred for bariatric surgery (Figure 1 ). The median age of patients was 56 years, 72% were female, and mean BMI was 42.6 kg/m 2 . Patients had a high prevalence of CV risk factors such as hypertension (58%), dyslipidemia (35%) and T2D (28%) ( Table 1) .

Elevated NT-proBNP levels were observed in 72 patients (23%), the distribution of 130 NT-proBNP levels is shown in Figure 1 . A history of CV disease was present in 64 of the 310 J o u r n a l P r e -p r o o f patients (21%) ( Table 1) . Patients with elevated NT-proBNP levels more often had a history of CV disease (42% vs 14%) and also used more CV drugs. There were 31 patients with a history of coronary artery disease, but in general NT-proBNP levels were not increased in these patients. A history of atrial fibrillation was present in 22 Of the 55 patients with LVEF ≥ 50%, 13 had evidence for structural heart disease on echocardiography: left atrial enlargement (n=9), left ventricular hypertrophy (n=4), and/or evidence of diastolic dysfunction (n=3; patients may have more than one criterion). Using 160 our work-up, this means that the observed increased NT-proBNP levels in concert with the echo data, resulted in newly found biochemical and echocardiographic evidence for heart failure with preserved ejection fraction (HFPEF) [19] in 13 of these 55 patients (Figure 3 ).

In six of the 67 patients, additional diagnostic tests were done. One patient with a 165 history of coronary artery bypass surgery had recurrent cardiac events of chest pain and myocardial ischemia, and underwent percutaneous coronary intervention. In two additional patients, coronary angiography was performed, which showed no coronary lesions, but both were found to have heart failure. Three patients had abnormalities on ECG, which led to 24hour Holter ECG in two of them, and a cardiac MRI in the other, none of these three patients 170 was diagnosed with a new CV disease. All six patients were subsequently accepted for surgery.

As a result of cardiac work-up, cardiovascular drug regimens were adjusted in nine patients. in seven patients, new drugs were prescribed (diuretics n=2, statins n=2, beta blocker n=1, ACE-inhibitor n=1, calcium channel blocker n=1). In the remaining two patients, 175 adjustment of beta blocker dosage was instructed for one, and a diuretic was ceased in another. In five other patients, the treating cardiologist ordered perioperative instructions on cardiovascular drugs, fluid balance or oral anticoagulants. 

The main purpose of this study was to determine the prevalence and incidence of subclinical or unrecognized CV disease in patients ≥50 years scheduled for bariatric surgery using 195 plasma NT-proBNP. NT-proBNP was increased in 72 (23%) of the 310 patients. Of the 67 patients who underwent thorough cardiac evaluation, echocardiographic evidence of structural and/or functional remodeling was present in 25 patients (37%), and only four of these 25 patients had a medical history of heart failure. This means that this non-invasive, simple and cheap diagnostic tool could be used to detect new of structural and/or functional 200 remodeling in a high-risk patient population that is evaluated for bariatric surgery.

Natriuretic peptides such as NT-proBNP and brain natriuretic peptide (BNP) are most often used for monitoring patients with established heart failure, and both have important J o u r n a l P r e -p r o o f clinical and prognostic value for long-term outcome [21] . In addition, these biomarkers are powerful tools to predict new onset heart failure [22] . Interestingly, in addition to heart 205 failure and atrial fibrillation, NT-proBNP levels also strongly predict other CV events, such as myocardial infarction and stroke [23] . Therefore, NT-proBNP could be a reliable screening tool for CV disease. However, in our results we mainly observed elevated plasma NT-proBNP in patients with heart failure or atrial fibrillation, and to a lesser extend in patients with coronary artery disease. Therefore, the use of NT-proBNP as a screening tool for CV diseases 210 may be best used for new-onset heart failure.

NT-proBNP and BNP have been evaluated for their prognostic value as cardiac screening tools to predict the development of (major) cardiac events [14, 24] . In our cohort, no CV events occurred in the postoperative phase, though unlikely, this might have been influenced by alterations in CV drugs during cardiac work-up. In general, there is limited data 215 available on the incidence of cardiac complications following bariatric surgery, but in general the incidence is low, ranging between 0.1-1.7% [25, 26] . So far, no studies have examined the association between pre-operative cardiac screening and outcome after bariatric surgery.

Two meta-analyses concluded that single preoperative measurements of either NT-proBNP or BNP are both good predictors for cardiovascular complications [14, 24] . These meta-analyses 220 examined patients that were undergoing non-cardiac surgery, and several studies did evaluate patients undergoing (major) abdominal procedures, but not specifically patients undergoing bariatric surgery. Procedures that were examined in these meta-analyses were mainly classified as high risk for development of cardiac complications, while bariatric surgery is classified as a procedure with intermediate risk [14] . Elevated BNP or NT-proBNP 225 levels were associated with an increased risk for the development of cardiovascular complications (odds ratio of 19.3 [95% CI 8.5-43.7]) [24] , and an area under the curve (AUC) of J o u r n a l P r e -p r o o f the relative operating characteristic (ROC) for the predictive value of elevated BNP or NT-proBNP levels was 0.70 (95% CI 0.66 -0.74) [14] . In a more recent prospective study including more procedures with an intermediate risk of cardiac complications, the AUC was 0.88 (95% 230 CI 0.82-0.93) for preoperative NT-proBNP measurements [27] . Outcomes consistently show that heart failure is an independent predictor for major adverse cardiac events (MACE) [28] .

As an alternative for a single measurement screening tool for major cardiac adverse events, several risk assessment tools have been tested in non-cardiac surgery patients, such as the 6-item Revised Cardiac Risk Index that indicates whether preoperative cardiac assessment 235 should be performed [29] . Two newer prediction models are available as online tools for risk assessment of MACE and integrate 23 and 30 items [30, 31] . However, none of these prediction tools are validated in bariatric study patients and might not be sensitive enough. Given the lack of a validated screening tool for CV disease and high prevalence of occult LV dysfunction (and heart failure) in our cohort, it is somewhat surprising that in the recently reported 240

Clinical Practice Guidelines for patients undergoing Bariatric Surgery, standard preoperative evaluation of (high risk) patients in order to detect occult CV disease -in selected patients-is also not discussed [6] .

With current acceptably low morbidity and mortality rates in the early phase after bariatric surgery, and the evident long-term improvements in weight loss and CV disease, it 245 is likely that the number of patients eligible for bariatric surgery will further increase.

Moreover, it is conceivable that obese patients with specific CV diseases such as heart failure and atrial fibrillation, will be considered candidates for bariatric or metabolic surgery, not just to induce weight loss, but specifically to treat these comorbidities [6] . Especially for these patients at high-risk of developing CV complications, accurate pre-operative CV screening is 250 important. Therefore, NT-proBNP assessment could prove to be the first choice as a screening tool, since it is cheap, easy and non-invasive.

There are some limitations that merit emphasis. First, this is a single center study with a relatively small sample size. Therefore, the results may not provide conclusive evidence whether cardiac screening is beneficial, in terms of reducing CV morbidity and 255 mortality. Second, patients with normal NT-proBNP levels were not referred for ECG or echocardiography, therefore the presence of CV disease is unknown in these patients.

However, it has been established that a normal BNP or NT-proBNP makes it very unlikely that a patient has CV disease, especially heart failure [19] . It should also be noted that NT-proBNP is a stronger predictor for heart failure than coronary artery disease and stroke, 260 albeit we did identify two patients in our cohort that required intervention for coronary artery disease while using NT-proBNP [13, 23] . Third, the aim of our study was to examine the value of NT-proBNP as a screening tool for CV disease, and was consequently not powered to examine a potential association with post-operative cardiovascular outcome. Fourth, NT-proBNP has an inverse relation with BMI [32] , which means that patients with potential CV 265 disease could have false negative outcome of cardiac screening with NT-proBNP. This implies that the reported 23% of patients with elevated NT-proBNP in our study is probably an underestimation of the actual number of patients with CV disease. Fifth, use of NT-proBNP as a single screening tool might be less predictive for CV disease than a prediction model that combines NT-proBNP with levels of additional laboratory measurements (such as 270 troponins or highly sensitive C-reactive protein) and presence of comorbidities such as diabetes. However, we aimed to investigate NT-proBNP a simple and stand-alone diagnostic tool, and we thus did not add other parameters to the decision whether or not patients should be referred for cardiac work-up. Last, it is likely that our cohort of patients is slightly J o u r n a l P r e -p r o o f different than the general obese population. General practitioners may be reluctant to refer 275 a patient for bariatric surgery if they have CV disease such as congestive heart failure or recent myocardial infarction, due to a higher risk of fatal complications following bariatric surgery [33] .

Elevated levels of NT-proBNP levels are present in almost one fourth of obese patients aged ≥ 50 years undergoing bariatric surgery. In more than one third of them, there was echocardiographic evidence for LV structural and functional remodeling. Further studies are needed to assess if these preliminary results warrant routine application of NT-proBNP to identify patients at risk for CV complications after bariatric surgery. 285

The authors have no commercial associations that might be a conflict of interest in relation to this article.

J o u r n a l P r e -p r o o f 

Mechanisms, pathophysiology, and management of obesity

Management of obesity

Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years

Obesity and prevalence of cardiovascular diseases and prognosis -the obesity paradox updated

State-Level Prevalence of Adult Obesity 300 and Severe Obesity

Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures -2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology

IFSO Worldwide Survey 2016; primary, endoluminal and revisional procedures

Low overall mortality during 10 310 years of bariatric surgery: nationwide study on 63,469 procedures from the Scandinavian Obesity Registry

Metabolic surgery. Weight loss, diabetes, and beyond

Perioperative and 1-year outcomes of bariatric surgery 315 in septuagenarians: implications for patient selection

Challenges in cardiac risk assessment in bariatric surgery patients

Evaluation and treatment of patients with cardiac disease undergoing bariatric surgery

N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population

The predictive ability of pre-operative B-type 325

natriuretic peptide in vascular patients for major cardiovascular events. An individual patient data meta-analysis

Prognostic value of peri-operative Nterminal Pro-B-Type natriuretic peptide in in non-cardiac surgery

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Heart Failure Association of the European Society 335 of Cardiology practical guidance on the use of natriuretic peptide concentrations

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

B-type natriuretic peptide and prognosis in 350 heart failure patients with preserved and reduced ejection fraction

Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

Is a pre-operative brain natriuretic peptide or Nterminal pro-B-type natriuretic peptide measurement an independent predictor of adverse 360 cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies

Early cardiac complications after bariatric surgery: does the type of procedure matter? Surg Obes Relat Dis

The comparative effectiveness of sleeve gastrectomy, gastric bypass, and adjustable gastric banding procedures for the treatment of morbid obesity

NT-proBNP incorporated in prediction rule of major perioperative adverse cardiac event in non-cardiac surgery

ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Derivation and prospective validation of a 375 simple index for prediction of cardiac risk of major noncardiac surgery

Optimizing ACS NSQIP modeling for evaluation of surgical quality and risk: patient risk adjustment, procedure mix adjustment, shrinkage adjustment, and surgical focus

Development and validation of a risk calculator for prediction of cardiac risk after surgery

Associations of Body Mass Index With 385 Laboratory and Biomarkers in Patients With Acute Heart Failure. Circ Heart Fail

Predictive factors of mortality in bariatric surgery: data from the Nationwide Inpatient Sample